Pradip Nair, Ph.D.
Pradip Nair is advising Equillium on CD6 biology and anti-CD6 mAb development.
Pradip is currently Principle Scientific Manager at Biocon and leads the drug discovery group where he worked extensively in the development of several novel monoclonal antibodies approved in India including BIOMAb™ (anti-EGFR) for head and neck cancers and ALZUMAb™ (anti-CD6) for moderate to severe plaque psoriasis. He and his team played a pivotal role in advancing the understanding of the CD6 pathway and the mechanism of action of modulating anti-CD6 mAbs. Additionally, Pradip was involved in the development of bioassays for several biosimilar products manufactured by Biocon including trastuzumab, bevacizumab and Pegfilgrastim. Pradip has authored 16 scientific papers and holds two patents related to anti-CD6 mAbs granted in the U.S.
Pradip received his Master of Science in Zoology, specializing in molecular biology and biochemistry, from the Benares Hindu University, Varanasi, India. He obtained his Ph.D. from the Regional Cancer Center, Trivandrum, India under a Council for scientific and industrial research (CSIR) junior and senior research fellowship. Pradip completed his post-doctoral work at the National Center for Biological Sciences, Tata Institute of Fundamental research, Bangalore under a Department of Science and Technology (DST) fast track young scientist award.